FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma
Cancer · 15.05.2023 · 129 (10) · 1465-1466
DOI: 10.1002/cncr.34810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 23.04.2023. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Agents, Lymphoma, Non-Hodgkin, Antibodies, Bispecific. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Adult patients with relapsed or refractory follicular lymphoma now have access to a new treatment option. Mosunetuzumab-axgb was granted accelerated approval by the US Food and Drug Administration on December 22, 2022.1 Mosunetuzumab is a bispecific antibody that represents a new class of fixed-duration cancer immunotherapy. “Mosunetuzumab is an exciting new tool to treat patients with multiple relapsed follicular lymphoma,” says Jason Romancik, MD, an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. “Patients who have follicular lymphoma that has relapsed multiple times often have a poor prognosis, so the development of a new, off-theshelf immunotherapy that is efficacious, safe, and accessible to patients represents a significant advance in the field. It will also give more access [to] those who have limited standardof-care options left to treat their lymphoma but [who] are unable to participate in the ongoing confirmatory trials investigating this medication.” The approval was based on response rates shown in a singlearm, multicenter, phase 2 study of 90 patients with relapsed or refractory follicular lymphoma treated with mosunetuzumab (the GO29781 trial).2, 3 All patients were enrolled in the trial between May 2019 and September 2020 and had received at least two prior lines of systemic therapy. Among the 90 patients, 77% had stage III/IV disease; patients had tried 2–10 previous lines of therapy (median of three prior therapies). A total of 53% of the patients did not respond to two prior lines of anti-CD20 therapy and alkylator therapy. At a median of 26.7 months (as of May 20, 2022), the objective response rate was 77.8%, and the complete response rate was 60%. Among the complete responders, 79.5% remained in remission for at least 24 months. Efficacy outcomes seen with mosunetuzumab were all improved in comparison with those seen with the patients’ last prior therapy (chemoimmunotherapy in 63%, PI3K inhibitor–containing therapy in 8%, anti-CD20 antibodies plus lenalidomide in 2%, chimeric antigen receptor T-cell therapy in 2%, and other therapies in 25%). The most common adverse events that occurred in 20% of the patients or more included cytokine release syndrome (CRS), fatigue, rash, pyrexia, and headache. At last report, a total of 44.4% of the patients had developed CRS; all of these cases were resolved. (A boxed warning on the prescribing label warns of serious life-threatening CRS, including neurologic toxicity, infections, cytopenias, and tumor flare.) Commenting on the 44.4% of the patients in the study who developed CRS, Dr Romancik notes that 90% of the cases were grade 1–2 in severity, and most occurred during the first cycle of treatment. Although hospitalization for CRS monitoring was not mandatory in the trial, Dr Romancik believes that there is a need to be ready for this potential complication. “Providers who will be using this medication need to develop protocols for monitoring and managing this side effect and have a health care facility available to admit the patient for management if needed,” he says, adding that there is no consensus to date on how to monitor CRS in patients, especially in the community setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Nierengarten, M. B. (2023). FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma. Cancer, 129(10), 1465-1466. https://doi.org/10.1002/cncr.34810
Vancouver
Nierengarten MB. FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma. Cancer. 2023;129(10):1465-1466. doi:10.1002/cncr.34810
BibTeX
@article{Nierengarten2023,
author = {Nierengarten, Mary Beth},
title = {FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma},
journal = {Cancer},
year = {2023},
volume = {129},
number = {10},
pages = {1465--1466},
doi = {10.1002/cncr.34810}
}
EUVIMED